MyPatientPal+: A Smartphone App and a Provider Dashboard to Manage Patient Care While on Treatment
The overall goal of this clinical trial is to assess the feasibility of implementing MyPatientPal+ a smartphone app and provider dashboard, to collect daily patient-reported outcome data from patients and share with providers to improve the effective management of treatment-related side effects
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study focuses on testing the effectiveness of MyPatientPal+, the combination of MyPatientPal smartphone app and a newly developed provider dashboard, on patient quality of life, adherence to medications, and severity of side effects on patients who are on cancer treatment. Participants will use the MyPatientPal+ smartphone daily to complete daily patient reported outcome questions (PROs) for 8 weeks. Providers will enter information as desired and not on a set schedule.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Lead Clinical Research Associate
- Telefonnummer: +1 313-576-9735
- E-post: phalorej@karmanos.org
Studieorter
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Karmanos Cancer Institute
-
Kontakt:
- Lead Clinical Research Associate
- Telefonnummer: +1 313-576-9735
- E-post: phalorej@karmanos.org
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Patients-
- 18-70 Years of age
- have a diagnosis of breast, any gastrointestinal, lung, prostate, head and neck, or bladder cancer
- about to initiate chemotherapy using one of the regimens listed in the protocol
- be able to speak, read, and write English
- willing and able to provide consent
- have access to a stable internet connection
Providers:
- being a practicing oncologist
- treating patients at Karmanos Cancer Institute (KCI) who are enrolled and consent to using the MyPatientPal+ smartphone app
- provide consent for the study
Exclusion Criteria:
Patients-
- cognitive or perceptual disturbances that prevent completing study measures Provider-
- None
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: MyPatientPal+ Smartphone Application
Participants report daily side effects and medications. Application includes a provider dashboard to track patients side effects and medications. |
The intervention will consist of patients using the MyPatientPal+ application to complete daily patient reported outcome questions (PROs) of: (a) patient quality of life, (b) medication use, and (c) severity of side effects, and their providers who will elect to receive a weekly summary of patient's daily PRO reports electronically (e.g., email) or through the dashboard. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Single-item daily Quality of Life (Patient)
Tidsram: Daily for 8 weeks
|
Patients will report their daily quality of life daily using MyPatientPal smartphone app. The question: "How was your quality of life today?" has a 7-point scale ranging from 1=very poor to 7=excellent. |
Daily for 8 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Adherence to medications (patient)
Tidsram: Daily for 8 weeks
|
Patients will report any medications they are taking related to their treatment. Each report will consist of them answering a forced-choice question about whether each of their prescribed medications was taken (0=yes, 1=no). The investigators will compare the ratio of total days of adherence/total number of days per medication between the weekly and daily reporting phases. There will be no set number of medications that will be assessed given that the app will be set up to record only those medications the patient is prescribed, but on average, most patients will report on 3 medications. Examples may include Xeloda, Ibrance, Femara, Tamoxifen, Remeron, Reglan, or Compazine. |
Daily for 8 weeks
|
|
Severity of side effects (patient)
Tidsram: Daily for 8 weeks
|
The severity of treatment-related symptoms will be examined as the primary outcome. Patients will report the severity of symptoms selected to match their current or expected side using the National Cancer Institute (NCI) CTCAE (Common Terminology Criteria for Adverse Events). Examples include diarrhea, constipation, vomiting, fever, and fatigue. Patients will be asked to mark the severity of each symptom using a 5-point rating scale (from 0=none to 4=very severe). |
Daily for 8 weeks
|
|
Patient quality of life
Tidsram: Weekly for 8 weeks
|
Patients will report their quality of life using the FACT-G (Functional Assessment of Cancer Therapy), a widely accepted measure of general functioning and quality of life among cancer patients. The measure has a total score and also four subscales assessing social, functional, emotional, and physical domains. |
Weekly for 8 weeks
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Felicity Harper, Ph.D., Barbara Ann Karmanos Cancer Institute
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Patologiska processer
- Genitala neoplasmer, manliga
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Genitala sjukdomar, manliga
- Prostatasjukdomar
- Manliga urogenitala sjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Luftvägssjukdomar
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Lungsjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Hudsjukdomar
- Bröstsjukdomar
- Urologiska neoplasmer
- Sjukdomar i urinblåsan
- Patologiska tillstånd, tecken och symtom
- Hud- och bindvävssjukdomar
- Prostatiska neoplasmer
- Lungneoplasmer
- Bröstneoplasmer
- Sjukdom
- Gastrointestinala neoplasmer
- Neoplasmer i huvud och hals
- Neoplasmer i urinblåsan
Andra studie-ID-nummer
- 2025-091
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .